Introduction {#sec1_1}
============

The etiology of primary open-angle glaucoma it still not well understood, despite all the extensive research available. Glaucoma is a multifactorial disease, and modifying only one factor (intraocular pressure -- IOP) limits our treatment. We know that the IOP is the most important risk factor, but it is known that the pressure does not necessarily have to be high for glaucoma to progress. A mechanism of disease causation would relate to alterations of ocular perfusion pressure \[[@B1]\], leading to glaucomatous damage of the optic nerve head (ONH).

In many studies, cardiovascular disease (CVD) was evidenced as a risk factor, even regardless of IOP \[[@B2], [@B3], [@B4]\]. This reinforces the importance of the vascular component in the pathogenesis of glaucoma (vascular theory). This theory sustains that glaucoma is caused by decreased ocular perfusion pressure, which affects ganglion cells at the ONH, and disease progression is enhanced by this vascular dysregulation \[[@B5]\]. Systemic hypotension, nocturnal blood pressure dipping, low diastolic perfusion pressure, and low ocular perfusion pressure has also been implicated with rapid disease progressors, especially in normal tension glaucoma (NTG) \[[@B6], [@B7]\]. Vascular diseases such as diabetes and CVD have not been consistently shown to be correlated with progression \[[@B3], [@B4]\].

Objective technologies such as the Heidelberg retinal tomography (HRT; Heidelberg Engineering, GmbH, Dossenheim, Germany) have been developed as adjuncts to subjective ONH evaluation. The HRT is a confocal scanning laser tomography device that creates reproducible and repeatable three-dimensional topographic images of the ONH and the peripapillary retina and had a different software that can aid evaluate progression through time, such as the topographic change (TCA) and trend analysis \[[@B8]\]. There is increasing evidence in the literature that TCA and trend analysis can detect progressive optic disc changes \[[@B9], [@B10], [@B11], [@B12]\].

The present report shows us the importance of these vascular factors and how treating one of them can change the apparent structural worsening of the disease in our patient with glaucoma.

Case Report {#sec1_2}
===========

Clinical History {#sec2_1}
----------------

A 69-year-old female with a single eye (history of retinal detachment surgery of the contralateral eye) and primary open-angle glaucoma treated with maximum medical topical therapy (timolol 0.5%, dorzolamide 2%, brimonidine 0.2%, and latanoprost 0.005%) presented at our clinic. Medical history included essential arterial hypertension, coronary insufficiency and episodes of angina pectoris.

Clinical findings were the following: central corneal thickness of 504 μm, vertical relation cup-to-disc ratio of 0.88, Shaffer gonioscopy of IV in three quadrants (with little pigment), crystalline opacity (LOCS III) NO1NC1C0P0 with basal examinations (visual field \[VF\] and HRT3) shown in Figure [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}.

Despite maximally tolerable antiglaucomatous topical treatment, intraocular pressure ranged between 18 mm Hg and 20 mm Hg. During the follow-up between 2013 and 2014 (8 months), she presented signs of progression in the trend analysis of HRT3 (Fig. [3](#F3){ref-type="fig"}), and it was decided then to perform a filtering surgery (trabeculectomy). The procedure was done without complications achieving IOP levels of 13 mm Hg on average, with a functional filtering bleb and without additional medical therapy.

However, 20 months later, the persistence of progression in the trend analysis and topographic analysis of changes (TCA) of HRT3 was evidenced (Fig. [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}). During this time, she maintained a mean IOP of 11 mm Hg throughout the follow-up. At this point, the problem was "What else can be done to halt this apparent progression in a patient with a single functional eye, if the pressure is controlled?" It was then decided to use medical treatment with brimonidine 0.20% twice a day, and a cardiological evaluation was also requested.

The following month, the cardiology department from a local hospital performed two cardiac catheterizations, after which the HRT3 parameters improved considerably (Fig. [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}). After 11 months, there is still improvement in HRT3 parameters; currently, the patient uses brimonidine 0.20% b.i.d. and has IOPs of 14 mm Hg. On average, VF examinations did not show any change throughout the follow-up (Fig. [5](#F5){ref-type="fig"}).

Discussion {#sec1_3}
==========

The HRT system allows us to evaluate the change over time with two protocols: trend analysis map and TCA \[[@B8], [@B9]\]. The TCA map is an event-based protocol for detecting topographic surface height changes across the entire ONH and peripapillary surface at a superpixel level between baseline and follow-up images. Progression is identified when the change exceeds measurement variability and is confirmed in, at least, 3 consecutive tests (error probability \<5%) and a cluster of 20 or more significantly depressed superpixels \[[@B9]\].

We have to remember that when talking about progression we cannot rely only on one test; nevertheless, some studies have demonstrated that there is a significant subset of patients who show TCA changes without ONH stereophotograph \[[@B9], [@B10], [@B11]\] or VF progression as was probably the case in our report. Like our case, some patients with open-angle glaucoma continue to progress despite an adequate decrease in the IOP. We know that there are several risk factors besides IOP, such as a thin central corneal thickness, pseudo-exfoliation, and other vascular entities like systemic hypotension, that have also been implicated in the progression and pathogenesis of glaucoma; this particular type of glaucoma is known as NTG and is explained by the "vascular theory" \[[@B13]\]. These patients have a low perfusion pressure of the ONH caused by an altered vascular regulation that eventually leads to unstable ocular perfusion, ischemia, and even damage by reperfusion of the head of the optic nerve \[[@B14]\].

There is evidence to suggest that low and fluctuating perfusion pressure are risk factors for the development of glaucoma \[[@B15]\]; reduced ocular blood flow is also associated with its progression and pathogenesis \[[@B16]\]. Patients with diabetes and arteriosclerosis are supposed to have reduced retinal blood flow due to the endothelial and capillary dysfunction from the microvascular damage of the disease, and this is evidenced by large clinical studies, which found a higher prevalence of glaucoma in these patients even independent from IOP \[[@B17], [@B18]\]. But ocular blood flow is not as simple as it looks, because the vascular factors related in the pathogenesis of NTG are unclear; oxidative stress, vasospasm, and endothelial dysfunction seem likely to be the cause of glaucomatous optic neuropathy.

CVD is an important risk factor for progression of glaucoma, perhaps independently of IOP \[[@B2]\]. Chan et al. \[[@B2]\] found that the progression of glaucoma was more rapid in patients with CVD, and these patients doubled the possibility of disease progression. Patients who had CVD in the rapid progression group of this study had lower IOP than controls, indicating that this could be an independent factor. Another study based on the Early Manifest Glaucoma Trial (EMGT) found that patients with CVD had a hazard ratio of 2.75 for glaucoma disease progression compared with non-CVD patients \[[@B3], [@B4]\].

This could explain the reason why our patient had a consistent change in the topographic and trend maps that suggested progression despite having good IOP levels (achieved with surgery and medication), and these changes improved only after a cardiac catheterization, suggesting that the structural progression stopped and even improved. One possible additional factor influencing this improvement could be the addition of brimonidine at that moment, but IOP levels were already low during the follow-up, and its neuroprotective mechanism or its additional effect on the pressure could probably explain this improvement.

We could not find any similar cases in the literature, so we believe it is a valuable report. The prevalence and effects of CVD in patients with glaucoma are well known from the large population trials published in the literature \[[@B19], [@B20], [@B21], [@B22], [@B23]\], but how these diseases relate to more aggressive progression, and which ones in particular, is not known yet. On the other hand, a few studies showed no association between CVD history and glaucoma progression \[[@B24], [@B25]\].

Thus, decreasing only the IOP for the treatment of glaucoma is not enough. A complete medical history is of tremendous importance in our patients with glaucoma, especially those with CVDs. The aim is to try to modify a risk factor that could decrease progression in these patients, and the therapeutic strategy should also include neuroprotection. If we can modify a risk factor, then it should be treated.
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![Baseline optic disc photograph, visual field, and Heidelberg retina tomography 3 parameters from 2013. Left eye shows diffuse rim thinning, with Moorfields regression classification outside normal limits.](cop-0010-0256-g01){#F1}

![Humphrey visual field examination from the initial evaluation. Left eye showed good reliability and a focal (cecocentral, paracentral, and inferior nasal) defect.](cop-0010-0256-g02){#F2}

![Heidelberg retinal tomography 3 trend analysis and follow-up. The left eye shows that despite trabeculectomy and apparently good intraocular pressure levels, progression continued, and only after the cardiac catheterism, the parameters improved.](cop-0010-0256-g03){#F3}

![Heidelberg retinal tomography 3. Topographic change analysis during follow-up showing improvement (green areas) after the cardiac procedure.](cop-0010-0256-g04){#F4}

![Humphrey visual field examination from the initial evaluation (2013 and after the cardiac procedure) showing the same focal defect with no changes.](cop-0010-0256-g05){#F5}
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